Wilmink J T, Lindeboom S F, Vencken L M, vd Burg W
Diagn Imaging Clin Med. 1984;53(4):208-14.
In a prospective double-blind randomized study involving 40 patients undergoing lumbar myelography, an attempt was made to correlate adverse effects of the examination with contrast medium dosage. Metrizamide for myelography is dispensed in two dosage aliquots, 3.75 and 6.75 g. In one group of 20 patients (10 males and 10 females) the higher dose was utilized routinely, in a second similar group the lower dose. 24 h after myelography complaints of headache were noted in 9 out of 40 patients; nausea, sometimes with vomiting, in 3 out of 40, and giddiness or light-headedness in 6 out of 40. No other side effects were registered. Complaints after myelography occurred significantly more often in females than in males, but there was no correlation between the incidence of complaints and the dose of metrizamide administered.
在一项涉及40例接受腰椎脊髓造影患者的前瞻性双盲随机研究中，尝试将检查的不良反应与造影剂剂量相关联。用于脊髓造影的甲泛葡胺以两种剂量分装，分别为3.75克和6.75克。在一组20例患者（10例男性和10例女性）中常规使用较高剂量，在另一组类似患者中使用较低剂量。脊髓造影后24小时，40例患者中有9例出现头痛主诉；40例中有3例出现恶心，有时伴有呕吐，40例中有6例出现头晕或头重脚轻。未记录到其他副作用。脊髓造影后的主诉在女性中比男性更频繁地出现，但主诉发生率与所给予的甲泛葡胺剂量之间没有相关性。
